Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corvus Pharmaceuticals reports Q4 loss, highlights CPI-818 potential and challenges

Corvus Pharmaceuticals showcased a mixed financial performance with a focus on managing cash burn rate and extending cash runway.
The company's strength lies in the potential of CPI-818 in various indications and the identification of a patient selection biomarker.
Challenges include cash management, regulatory hurdles in upcoming trials, and the need for clarity on biomarker validation.
Opportunities abound in market expansion, clinical development acceleration, and strategic initiatives for growth and value creation.

Corvus Pharmaceuticals reports Q1 progress with CPI-818 advancements

Corvus Pharmaceuticals reported financial improvements and progress in CPI-818 development.
Partnerships and upcoming trials indicate a promising future for the company.
Challenges lie in addressing analyst queries and ensuring trial success and data presentation.

Corvus Pharmaceuticals reports Q2 progress in cancer drug trials

Corvus Pharmaceuticals reported improved financials with reduced expenses and strategic stock sales, while advancing key drug trials in cancer treatment.
The company's focus on innovative drug development in cancer immunotherapy presents opportunities for growth and partnerships.
Challenges lie in managing expenses, conducting rigorous clinical evaluations, and balancing financial decisions with strategic priorities.

Corvus Pharmaceuticals reports Q3 progress in oncology and immune diseases

Corvus Pharmaceuticals reported a net loss of $6 million in Q3 2023 but showcased progress on soquelitinib and potential in ITK inhibition for immune diseases.
The company's financial overview and upcoming milestones indicate a strategic focus on advancing pipeline candidates and exploring partnerships.
While facing challenges in managing expenses and balancing resources, Corvus Pharmaceuticals has opportunities to drive growth through positive trial results and strategic partnerships.

Corvus Pharmaceuticals advances pipeline with promising therapies and partnerships

Corvus Pharmaceuticals showcased financial improvements and progress in their pipeline programs during Q4 2023 earnings call.
The company's focus on ITK inhibition and orphan drug designation for soquelitinib highlight their commitment to innovative therapies.
While facing cash challenges, Corvus is actively seeking partnerships and advancing trials to capitalize on commercial and medical opportunities.

Corvus Pharmaceuticals reports improved financials and promising clinical advancements

Corvus Pharmaceuticals demonstrated improved financials and strong clinical progress in Q1 2024, supported by recent financing.
The company's focus on Soquelitinib and ciforadenant presents promising opportunities for growth and advancement in the oncology space.
Challenges lie in operational scalability, trial design complexities, and the need for clear patient criteria and efficacy benchmarks.

Corvus Pharmaceuticals reports strong Q2 performance and advances key drugs

Corvus Pharmaceuticals demonstrated financial stability and clinical progress in Q2 2024, with a strong cash position and promising pipeline.
The company's focus on selective ITK inhibition for immune diseases and cancer shows commitment to innovative therapies and addressing unmet medical needs.
While facing challenges in trial expectations and resource allocation, Corvus Pharmaceuticals has opportunities for growth through portfolio diversification and milestone achievements.
Overall, Corvus Pharmaceuticals is well-positioned to capitalize on its strengths, navigate challenges, and seize opportunities in the biopharmaceutical market.

Corvus Pharmaceuticals reports Q3 losses but advances key cancer treatments

Corvus Pharmaceuticals' Q3 performance reflects increased R&D expenses but a secure financial position with available cash and potential additional funds.
The company's strengths lie in its strong pipeline, progress in key trials, and a stable financial runway into 2026 for upcoming milestones.
Challenges include addressing questions on trial specifics, competitive landscape scrutiny, and operational complexities in trial management.
Opportunities exist in advancing innovative treatments, exploring market potential, and addressing immunotherapy resistance in cancer therapy.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders.

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

HEICO

Tesla

U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday.

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m.

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus (CRVS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable

Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates within its developmental pipeline and recently kicked of a pivotal Phase 3 registrational study. Can the rally continue as the market increasingly buys into the story around Corvus or is some profit taking on the horizon?

Corvus Pharmaceuticals: The Market Likes The Story

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Li Watsek - Cantor Jiale Song - Jefferies Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Jeff Jones - Oppenheimer Operator Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2024 Business Update and Financial Results Conference Call. At this time participants are in a listen-only mode.

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) (“Corvus”) on behalf of the company's shareholders. The investigation seeks to determine whether Corvus and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions. Corvus shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or.

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company's presentation will be on Tuesday, September 10 at 12:00pm ET.

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early trials, more than double the current standard of care. The PTCL market, estimated at $500 million in the U.S., offers significant potential if Soquelitinib's Phase 3 trials are successful.

Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Richard Miller - Chief Executive Officer Leiv Lea - Chief Financial Officer Jeff Arcara - Chief Business Officer Jim Rosenbaum - Senior Vice President, Research Ben Jones - Senior Vice President, Regulatory and Pharmaceutical Sciences Conference Call Participants Li Watsek - Cantor Roger Song - Jefferies Aydin Huseynov - Ladenberg Jeff Jones - Oppenheimer Graig Suvannavejh - Mizuho Operator Good afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals Second Quarter 2024 Business Update and Financial Results Conference Call.

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript

Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to soquelitinib for the treatment of adult patients with relapsed or refractory peripheral T cell lymphoma (PTCL) after at least two lines of systemic therapy.

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well as potential partnerships with established therapies. Corvus recently completed a capital raise, securing $30M with potential for an additional $60M through warrants, signaling confidence in their Phase 3 trial and future growth.

Corvus Pharmaceuticals Is Ready To Take Flight

Intrusion

OPKO Health

One of the best ways to spot opportunities in penny stocks to buy is by following insiders. Most notably, insiders who are putting their money where their mouth is.

The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now

BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York from June 5-7, 2024. The Company's presentation will be on Wednesday, June 5 at 3:00 pm ET.

News for Corvus Pharmaceuticals Stock (CRVS)